IOL Chemicals & Pharmaceuticals reported a revenue growth of 8 percent at Rs 555.14 crore in quarter ended December 2021. The company had reported revenues of Rs 513 crore in same quarter last year.
Its Q3FY22 earnings before interest, taxes, depreciation, and amortization (EBITDA) declined 62 percent at Rs 59.21 crore against Rs 157.3 crore in Q3FY21.
The company's margins also declined to 10.7 percent versus 30.7 percent on a year on year basis. Its profits also declined by 65 percent at Rs 40.07 crore.
In an interview to CNBC-TV18 the company's CEO, Sanjay Chaturvedi said, he is confident of delivering 15 percent EBIT number on a sustainable basis.
He said the company is likely to see an improvement in topline and bottomline of non-Ibuprofen business.
Watch video for more.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
EVM unlocking controversy in Mumbai North West Lok Sabha seat — What we know so far
Jun 17, 2024 10:25 AM